

# Non-Small Cell Lung Cancer Medications Enrollment Form

## Medications A-K

(Avastin, Alecensa, Cyramza, Erlotinib, Gavreto, Imfinzi, Iressa, Keytruda)



Fax Referral To: 1-800-323-2445

Email Referral To: Customer.ServiceFax@CVSHealth.com

Phone: 1-800-237-2767

### Six Simple Steps to Submitting a Referral

#### 1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name: \_\_\_\_\_ Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_

Preferred Contact Methods:  Phone (to primary # provided below)  Text (to cell # provided below)  Email (to email provided below)

Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.

Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender:  Male  Female

Email: \_\_\_\_\_ Last Four of SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_

#### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_ State License #: \_\_\_\_\_

NPI #: \_\_\_\_\_ DEA #: \_\_\_\_\_ Group or Hospital: \_\_\_\_\_

Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_ Contact's Phone: \_\_\_\_\_

#### 3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

#### 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: \_\_\_\_\_ Ship to:  Patient  Office  Other: \_\_\_\_\_

##### Diagnosis (ICD-10):

Code: \_\_\_\_\_ Description: \_\_\_\_\_  Code: \_\_\_\_\_ Description: \_\_\_\_\_

Code: \_\_\_\_\_ Description: \_\_\_\_\_  Code: \_\_\_\_\_ Description: \_\_\_\_\_

##### Patient Clinical Information:

Allergies: \_\_\_\_\_ Weight: \_\_\_\_\_ lb/kg Height: \_\_\_\_\_ in/cm BSA: \_\_\_\_\_ m<sup>2</sup>

Biomarker(s):  ALK+  BRAF V600E  EGFR +  EGFR/T790M+  KRAS G12C+  METex14+  NTRK1/2/3+  RET+

ROS1+  PD-L1 <1%  PD-L1 ≥1%-49%  PD-L1 ≥ 50%  No actionable molecular marker

#### 5 PRESCRIPTION INFORMATION

DRUG NAME	STRENGTH	DOSE/DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Avastin	<input type="checkbox"/> 100 mg/4 mL <input type="checkbox"/> 400 mg/16 mL	<input type="checkbox"/> 15 mg/kg IV every three weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Alecensa	150 mg	<input type="checkbox"/> 4 capsules PO twice daily #240 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Cyramza	<input type="checkbox"/> 100 mg/10 mL <input type="checkbox"/> 500 mg/50 mL	<input type="checkbox"/> 10 mg/kg IV once every two weeks <input type="checkbox"/> 10 mg/kg IV once every three weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Erlotinib	<input type="checkbox"/> 25 mg <input type="checkbox"/> 100mg <input type="checkbox"/> 150 mg	<input type="checkbox"/> 1 tablet PO once daily #30 <input type="checkbox"/> 3 tablets PO once daily #90 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Gavreto	100 mg	<input type="checkbox"/> 4 capsules PO once daily #120 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Imfinzi	<input type="checkbox"/> 120 mg/2.4 mL <input type="checkbox"/> 500 mg/10 mL	<input type="checkbox"/> 10 mg/kg IV every two weeks <input type="checkbox"/> 20 mg/kg IV every three weeks <input type="checkbox"/> 1,500 mg IV every four weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Iressa	250 mg	<input type="checkbox"/> 1 tablet PO once daily #30 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Keytruda	100 mg/4 mL	<input type="checkbox"/> 200 mg IV every three weeks <input type="checkbox"/> 400 mg IV every six weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

#### 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

X \_\_\_\_\_

X \_\_\_\_\_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

# Non-Small Cell Lung Cancer Medications Enrollment Form

## Medications L-Z

(Libtayo, Lorbrena, Lumakras, Mekinist, Opdivo, Retevmo, Rozlytrek, Tabrecta, Tafinlar, Tagrisso, Tecentriq, Vizimpro, Xalkori, Yervoy, Zykadia)

### Please Complete Patient and Prescriber Information

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_  
 Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

### 5 PRESCRIPTION INFORMATION

DRUG NAME	STRENGTH	DOSE/DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Libtayo	350 mg/7 mL	<input type="checkbox"/> 350 mg IV every three weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Lorbrena	<input type="checkbox"/> 25 mg <input type="checkbox"/> 100 mg	<input type="checkbox"/> 1 tablet PO once daily #30 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Lumakras	120 mg	<input type="checkbox"/> 8 tablets PO once daily #240 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Mekinist	<input type="checkbox"/> 0.5 mg <input type="checkbox"/> 2 mg	<input type="checkbox"/> 1 tablet PO once daily #30 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Opdivo	<input type="checkbox"/> 40 mg/4 mL <input type="checkbox"/> 100 mg/10 mL <input type="checkbox"/> 240 mg/24 mL	<input type="checkbox"/> 240 mg IV every two weeks <input type="checkbox"/> 480 mg IV every four weeks <input type="checkbox"/> 360 mg IV every three weeks <input type="checkbox"/> 3 mg/kg IV every two weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Retevmo	<input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg	<input type="checkbox"/> 2 capsules PO twice daily #120 <input type="checkbox"/> 3 capsules PO twice daily #180 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Rozlytrek	<input type="checkbox"/> 100 mg <input type="checkbox"/> 200 mg	<input type="checkbox"/> 3 capsules PO once daily #90 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Tabrecta	<input type="checkbox"/> 150 mg <input type="checkbox"/> 200 mg	<input type="checkbox"/> 2 tablets PO twice daily #112 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Tafinlar	<input type="checkbox"/> 50 mg <input type="checkbox"/> 75 mg	<input type="checkbox"/> 2 capsules PO twice daily #120 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Tagrisso	<input type="checkbox"/> 40 mg <input type="checkbox"/> 80 mg	<input type="checkbox"/> 1 tablet PO once daily #30 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Tecentriq	<input type="checkbox"/> 840 mg/14 mL <input type="checkbox"/> 1,200 mg/20 mL	<input type="checkbox"/> 1,200 mg IV every two weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Vitrakvi	<input type="checkbox"/> 25 mg <input type="checkbox"/> 100 mg	<input type="checkbox"/> 1 capsule PO twice daily #60 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Vizimpro	<input type="checkbox"/> 15 mg <input type="checkbox"/> 45 mg <input type="checkbox"/> 30 mg	<input type="checkbox"/> 1 tablet PO once daily #30 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Xalkori	<input type="checkbox"/> 200 mg <input type="checkbox"/> 250 mg	<input type="checkbox"/> 1 capsule PO twice daily #60 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Yervoy	<input type="checkbox"/> 50 mg/10 mL <input type="checkbox"/> 200 mg/40 mL	<input type="checkbox"/> 1 mg/kg IV every six weeks <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
<input type="checkbox"/> Zykadia	150 mg	<input type="checkbox"/> 3 tablets PO once daily #90 <input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 1	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 2	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

## 6 PHYSICIAN SIGNATURE REQUIRED

PRODUCT SUBSTITUTION PERMITTED

(Date)

DISPENSE AS WRITTEN

(Date)

X \_\_\_\_\_ X \_\_\_\_\_

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates. ©2021 CVS Specialty and/or one of its affiliates. 75-55092A 061721 Page 2 of 2